

Overactive Bladder Drug-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/OCD88588F16MEN.html>

Date: March 2018

Pages: 157

Price: US\$ 3,480.00 (Single User License)

ID: OCD88588F16MEN

Abstracts

Report Summary

Overactive Bladder Drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Overactive Bladder Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Overactive Bladder Drug 2013-2017, and development forecast 2018-2023

Main market players of Overactive Bladder Drug in EMEA, with company and product introduction, position in the Overactive Bladder Drug market

Market status and development trend of Overactive Bladder Drug by types and applications

Cost and profit status of Overactive Bladder Drug, and marketing status

Market growth drivers and challenges

The report segments the EMEA Overactive Bladder Drug market as:

EMEA Overactive Bladder Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Overactive Bladder Drug Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Anticholinergics

Solifenacin

Oxybutynin

Darifenacin

Fesoterodine

Tolterodine

Trospium

Others

EMEA Overactive Bladder Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

EMEA Overactive Bladder Drug Market: Players Segment Analysis (Company and Product introduction, Overactive Bladder Drug Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma, Inc. (Japan)

Pfizer, Inc. (U.S.)

Teva Pharmaceutical Industries Limited (Israel)

Allergan, Plc (Ireland)

Medtronic plc (Ireland)

Mylan N.V. (U.S.)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Sanofi (France)

Apotex, Inc. (Canada)

Cogentix Medical, Inc. (U.S.)

Aurobindo Pharma Limited (India)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OVERACTIVE BLADDER DRUG

- 1.1 Definition of Overactive Bladder Drug in This Report
- 1.2 Commercial Types of Overactive Bladder Drug
 - 1.2.1 Anticholinergics
 - 1.2.2 Solifenacin
 - 1.2.3 Oxybutynin
 - 1.2.4 Darifenacin
 - 1.2.5 Fesoterodine
 - 1.2.6 Tolterodine
 - 1.2.7 Trospium
 - 1.2.8 Others
- 1.3 Downstream Application of Overactive Bladder Drug
 - 1.3.1 Idiopathic Bladder Overactivity
 - 1.3.2 Neurogenic Bladder Overactivity
- 1.4 Development History of Overactive Bladder Drug
- 1.5 Market Status and Trend of Overactive Bladder Drug 2013-2023
 - 1.5.1 EMEA Overactive Bladder Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Overactive Bladder Drug Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Overactive Bladder Drug in EMEA 2013-2017
- 2.2 Consumption Market of Overactive Bladder Drug in EMEA by Regions
 - 2.2.1 Consumption Volume of Overactive Bladder Drug in EMEA by Regions
 - 2.2.2 Revenue of Overactive Bladder Drug in EMEA by Regions
- 2.3 Market Analysis of Overactive Bladder Drug in EMEA by Regions
 - 2.3.1 Market Analysis of Overactive Bladder Drug in Europe 2013-2017
 - 2.3.2 Market Analysis of Overactive Bladder Drug in Middle East 2013-2017
 - 2.3.3 Market Analysis of Overactive Bladder Drug in Africa 2013-2017
- 2.4 Market Development Forecast of Overactive Bladder Drug in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Overactive Bladder Drug in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Overactive Bladder Drug by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Overactive Bladder Drug in EMEA by Types
 - 3.1.2 Revenue of Overactive Bladder Drug in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Overactive Bladder Drug in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Overactive Bladder Drug in EMEA by Downstream Industry
- 4.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Overactive Bladder Drug by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Overactive Bladder Drug by Downstream Industry in Africa
- 4.3 Market Forecast of Overactive Bladder Drug in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OVERACTIVE BLADDER DRUG

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Overactive Bladder Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 OVERACTIVE BLADDER DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Overactive Bladder Drug in EMEA by Major Players
- 6.2 Revenue of Overactive Bladder Drug in EMEA by Major Players
- 6.3 Basic Information of Overactive Bladder Drug by Major Players
 - 6.3.1 Headquarters Location and Established Time of Overactive Bladder Drug Major Players
 - 6.3.2 Employees and Revenue Level of Overactive Bladder Drug Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 OVERACTIVE BLADDER DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Astellas Pharma, Inc. (Japan)

7.1.1 Company profile

7.1.2 Representative Overactive Bladder Drug Product

7.1.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Astellas Pharma, Inc. (Japan)

7.2 Pfizer, Inc. (U.S.)

7.2.1 Company profile

7.2.2 Representative Overactive Bladder Drug Product

7.2.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Pfizer, Inc. (U.S.)

7.3 Teva Pharmaceutical Industries Limited (Israel)

7.3.1 Company profile

7.3.2 Representative Overactive Bladder Drug Product

7.3.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Limited (Israel)

7.4 Allergan, Plc (Ireland)

7.4.1 Company profile

7.4.2 Representative Overactive Bladder Drug Product

7.4.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Allergan, Plc (Ireland)

7.5 Medtronic plc (Ireland)

7.5.1 Company profile

7.5.2 Representative Overactive Bladder Drug Product

7.5.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Medtronic plc (Ireland)

7.6 Mylan N.V. (U.S.)

7.6.1 Company profile

7.6.2 Representative Overactive Bladder Drug Product

7.6.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Mylan N.V. (U.S.)

7.7 Endo International plc (Ireland)

7.7.1 Company profile

7.7.2 Representative Overactive Bladder Drug Product

7.7.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Endo

International plc (Ireland)

7.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)

7.8.1 Company profile

7.8.2 Representative Overactive Bladder Drug Product

7.8.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Hisamitsu Pharmaceutical Co., Inc. (Japan)

7.9 Sanofi (France)

7.9.1 Company profile

7.9.2 Representative Overactive Bladder Drug Product

7.9.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Sanofi (France)

7.10 Apotex, Inc. (Canada)

7.10.1 Company profile

7.10.2 Representative Overactive Bladder Drug Product

7.10.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Apotex, Inc. (Canada)

7.11 Cogentix Medical, Inc. (U.S.)

7.11.1 Company profile

7.11.2 Representative Overactive Bladder Drug Product

7.11.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Cogentix Medical, Inc. (U.S.)

7.12 Aurobindo Pharma Limited (India)

7.12.1 Company profile

7.12.2 Representative Overactive Bladder Drug Product

7.12.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Aurobindo Pharma Limited (India)

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OVERACTIVE BLADDER DRUG

8.1 Industry Chain of Overactive Bladder Drug

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OVERACTIVE BLADDER DRUG

9.1 Cost Structure Analysis of Overactive Bladder Drug

9.2 Raw Materials Cost Analysis of Overactive Bladder Drug

9.3 Labor Cost Analysis of Overactive Bladder Drug

9.4 Manufacturing Expenses Analysis of Overactive Bladder Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF OVERACTIVE BLADDER DRUG

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Overactive Bladder Drug-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/OCD88588F16MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OCD88588F16MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970